In aggregate, a possible merit connoted with CSPG4-CAR-T cells in AML is the exertion of anti-leukemia activity against CSPG4-positive blasts without affecting HSCs, which were found to be universally CSPG4-negative [87]. This evidence concerns the gene CSPG4 and acute myeloid leukemia.